Shareholders meeting

Ajanta Pharma Limited Ajanta Tower, 54-A, M Vasanji T +91 22 6060 9000 Road, Chakala, Andheri (E), E legal.info@ajantapharma.com Mumbai 400 093, India W www.ajantapharma.com 18th June 2026 BSE LIMITED National Stock Exchange of India, Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot no. Dalal Street, C/1, G Block, Bandra Kurla Complex, Mumbai – 400001 Bandra (East), Mumbai – 400 051 Scrip Code: BSE – AJANTPHARM 532331 Scrip Code: NSE AJANTPHARM EQ Sub.: Regulation 34 - Annual Report for financial year 2025-26 Dear Sir/Madam, We hereby inform that the Forty-Seventh Annual General Meeting (‘AGM’) of the Company will be held on Thursday, 16th July 2026 at 11.00 a.m. through Video Conferencing (“VC”)/ Other Audio-Visual Means (“OAVM”). Pursuant to Regulation 34(1) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Annual Report and Business Responsibility & Sustainability Report of the Company for the financial year 2025-26 along with Notice of the AGM. The Annual report, Business Responsibility & Sustainability Report and the Notice of AGM are being sent through electronic mode to members whose e-mails ids are registered and the same are also uploaded on the Company's website https://www.ajantapharma.com/assets/frontend/images/investors/files/annual_results/178175 8151_AjantaPharma-AR-2025-26.pdf. Letter containing the QR code & path/web-link to access Annual Report will be sent to those shareholders who have not registered their email IDs with the Company/ Depositories/ Registrar and Share Transfer Agent. Kindly take the same on your records. Thanking you, Yours faithfully, Gaurang Shah Sr. VP – Legal & Company Secretary Corporate Identity Number - L24230MH1979PLC022059 Strong Performance. Strong Performance. Accelerating Growth. Accelerating Growth. ANNUAL REPORT 2025-26 ANNUAL REPORT 2024-25 Contents Highlights of FY 2026 Strong 02 Corporate Overview J Performance. 5,453 Ajanta at a Glance cr. Accelerating Letter to Stakeholders Revenue Financial Highlights Growth. Our Businesses 16 J Our Enablers 1,498 21 Statutory Reports EBITDA* Management Discussion and Analysis Directors’ Report 1,056 Report on Corporate Governance cr. Business Responsibility and Sustainability Report 124 Financial Statements Consolidated Fiscal Year 2026 has been a year of great achievement — one where the investments Standalone we have been making in markets, products and people have come together to deliver 264 results that are not only strong today but Notice also lay a lasting foundation for the years ahead. The multi-dimensional growth engines that we have developed over the years, ensure the surety and sustainability of our consistent growth in earnings. Our theme for this Annual Report, “Strong Performance. Accelerating Growth”, reflects precisely where we stand: performing with discipline and poised to accelerate with purpose, confidence, and the conviction *Adjusted EBITDA after removing mark-to- To know more about Ajanta Pharma market forex loss that the best is yet to come. CORPORATE STATUTORY FINANCIAL NOTICE OVERVIEW REPORTS STATEMENTS ABOUT US Our Business is Well Diversified and Gives Us an Edge Ajanta Branded Generics - India Branded Generics - Asia US Generics 6 8 49 at a Glance Therapy Segments Therapy Segments Active ANDAs (excld. 6 Tentative) ~50% Leadership First-to-market In Sub-therapeutic Segments Under Approval 350+ 250+ ANDAs Products Products 49 Products on Shelf Branded Generics - Africa Africa Institutional 8 Antimalarial Therapy Segments Therapy Segment Leading 1st Brands in Segments Generic Prequalified by WHO 250+ 1 Bn+ 33+ Growth Levers Products Patients Treated Countries 600+ Market-wise Sales Contribution Products New product Market share Thrust on new launches across gain in existing countries and 6,000+ markets products therapies Strong product Focus on field Adding therapies, 68% Medical portfolio under force productivity products and field staff Branded Generics Representatives development/ enhancement in new countries registration 13,000+ FY 2026 Sales Ajantaites 30% 31% 22% 16% 3% 29% I 5,407 cr. Africa Optimise expenses Focus on India Asia Africa Institutional US Generics Focus on digitisation costs optimisation Across all functions of the organisation 02 | Ajanta Pharma Limited Annual Report 2025-26 | 03 CORPORATE STATUTORY FINANCIAL NOTICE OVERVIEW REPORTS STATEMENTS LETTER TO STAKEHOLDERS Our US Generics business posted approaching this with the same robust growth of 49% this year rigour and discipline that defines on the back of a few successful everything we do at Ajanta Pharma. Revenue from operations In the New League launches in the last 15 months. While the US Generics market is often Looking Ahead grew a robust 17% to characterised as volatile, we have with Confidence I 5,453 cr. Adjusted EBITDA consistently demonstrated that with As we look to FY 2027 and beyond, grew by 18% to I 1,498 the right portfolio strategy, supply we do so with conviction. The reliability, and commercial execution, cr. and margin stood at investments of the past years in it is possible to grow substantially 27%. PAT grew by a 15% to our field force, new therapies, new without compromising profitability. geographies, product pipeline, and I 1,056 cr. and margin stood Our Antimalarial Institutional Business people are entering their productive While we take satisfaction at 19% for the year. in Africa recorded a 9% growth for the phase. Our Branded Generics in the performance of our year, though initially we estimated it businesses in both India and established businesses, we to be on a declining trend. This is a emerging markets are well positioned and energy-efficiency measures lumpy business due to the reliance for strong growth. Our US business are equally energised by the implemented during the year, Ajanta on sponsors for the WHO-led will continue to scale responsibly. new frontiers we are actively programme. We still remain optimistic reduced carbon emissions by 11,590 We remain committed to the tonnes of CO . We also strengthened building. Ajanta Pharma about its performance going forward. 2 principles that have guided Ajanta efforts towards water conservation, is at a pivotal moment of Pharma through every phase responsible waste management Financial Highlights growth realisation—the of its evolution: quality without and plastic neutrality to enhance Revenue from operations grew a compromise, growth with margin operational sustainability. inflection point where years robust 17% to H 5,453 cr. Adjusted discipline, and stakeholder value These initiatives strengthen our of investment in products, EBITDA grew by 18% to H 1,498 cr., creation with integrity. resilience and will support sustainable people, and geographies and margin stood at 27%. PAT grew growth in the years ahead. by 15% to H 1,056 cr., and margin People Practices begin to compound into On behalf of the Board of Directors stood at 19% for the year. At Ajanta, excellence is a way of and the entire leadership team accelerated returns. We remain confident of maintaining life. We have always believed that at Ajanta Pharma, we extend our EBITDA margin in the coming year as our true strength lies in our people. deepest gratitude to each of our well while making further investment As we grow and expand into new shareholders for the trust you in developing our market. markets, strengthen our R&D pipeline, continue to place in us. We thank enhance operational excellence, our employees for their relentless New Growth Drivers: Dear Stakeholders, Segment Review The structural resilience of our and raise the bar of quality, one commitment, our customers and diversity in markets was once again Building for Tomorrow thing becomes increasingly clear: we healthcare professionals for their It is with immense pride and gratitude Our portfolio spans Branded Generics on full display in our Emerging must c [Showing first 8,000 characters — download PDF for full document]